Since it is possible to perform major surgi(al interventions on patients waith lowered prothromibinpIoconveltin concentration we have selected a group of patients suffering from mitral stenosis for further evaluation of this prophylactic measure. These patients are highly predisposed to thromiboembolic complications. The subsequent dosage was determined by the response. Individual variations often occur.5 Low prothrombin levels on the day of operation were corrected by the use of vitamin K, (20 to 50 mg. vitamin KI, Geigy).6 Dicumarol was usually given 1 to 2 weeks preolperatively and 3 weeks postoperatively until the patient was effectively ambulatory.
ment w-hen discharged from the hospital and continued this therapy as out-patients. On the whole, the treatment was stopped when the patient was as effectively mobile as before the operation. In two cases, however, the treatment was discontinued shortly after the operation. One of these patients developed severe icterus (possibly due to preoperative blood transfusions: hemolytic icterus); ini the other case the treatment was stopped by mistake six days after the operation. A typical curve of the prothromi bini-pro-(colnvertini level during the period of treattment and the daily doses of di(cuimarol is shown in figure 1. mg.. 10 above 1000 ml.
5 below 510 ml. 5 above 1060 ml.
5 below 480 ml. 5 above 740 ml.
Distribution 10 above 1500 ml. 14 between 1000-1500 ml. 25 between 500-1000 ml.
1 nothing. 5 above 1500 ml. 17 between 1000-1500 ml. 4 between 500-1000 ml. 2 above 1500 ml. 10 between 1000-1500 ml. 14 between 500-1000 ml.
the other Dicumarol-treated patients in the postoperative period (3 to 4 weeks).
In the control group, four patients had had thromboembolic attacks before surgery; two of these patients developed lung infarction postoperatively.
The number of control patients with postoperative thrombotic incidents confirmed clinically was six: one died of cerebral embolism, another still has paralysis of the right arm due to cerebral embolism. Two patients recovered from cerebral embolism and two from pulmonary infarction. In addition, two other control patients suffered from probable post- However, long-term anticoagulant therapy with Dicumarol has been shown to reduce thromboembolism in patients with mitral stenosis, atrial fibrillation and congestive heart failure.'0' 11, 12, 13 Cerebral embolism is the most frequent cause of death after mitral commissurotomy. This was stated by Bailey'4 who found 12 cases (5 per cent) of cerebral embolism in 235 patients operated on for mitral stenosis. Eight of these 12 patients died. In Bigelow's report,8 mitral commissurotomy was performed in 88 patients. The total number of thromboembolic episodes was 17 (20 per cent of the cases) and six showed postoperative cerebral embolism (one died). In 150 patients followed-up, the total number of fatal cerebral embolism was six (4 per cent of the patients). The figures of Warren'5 are also striking: 15 (16 per cent) out of 92 patients with mitral stenosis developed embolic episodes postoperatively after commissurotomy. The incidence was higher in a group of patients who previously had had embolic episodes and also in patients with atrial fibrillation. Baden'6 analyzed 106 cases of mitral stenosis operated on at the University Hospital of Copenhagen. Postoperative thromnboembolic complications occurred in 20 per cent. Twelve patients died after the operation and in eight of these cases, death was caused by cerebral embolism a few days after the operation.
Anticoagulant prophylaxis with Dicumarol has been used successfully after surgical operations and has reduced the frequency of thromboembolic complicatiolns.'7' 18 Usually this therapy has been initiated after the operation, but in some instances the first dose of Dicumarol has been administered on the evening before surgical intervention.7 Because of the lag, this prophylaxis has not been effective on the day of and the days immediately following the operation. In a previous paper, a more effective Dicumarol prophylaxis during major surgery was proposed" 2 and this prophylaxis has since been carried out in about 100 patients predisposed to thromboembolism. This treatment is begun one to two weeks prior to the operation ill order to get an idea of the patient's response to Dicumarol and to find the maintenance dose of Dicumarol.
The prothrombin level oin the day of operation must be above the bleeding limit (5 to 10 per cent), but must also lie in the therapeutic range. A standardized and sensitive method for the control of the therapy is therefore essential.
As most postoperative thromboembolic complications occur ill the first 10 to 12 days after the operation, the anticoagulant prophylaxis should be maintained at least in this period, ideally 2 to 3 weeks and even longer in a case of atrial fibrillation.
Obviously, uncontrollable bleeding is the main risk of this procedure, but this has not occurred in this small group of patients.
Thromboembolic complications occurred among the control patients with the usual expected incidence, but none of the Dicumarol treated patients developed thrombotic diseases during the periods of treatment. Though the number of patients ill the two groups is too small to allow a definite conclusion at the present time, our results as presented here have shown that an effective anticoagulant prophylaxis with Dicumarol can be maintained during mitral coommissurotomy. The 
